Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.50 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.36 |
| ▸ | CCKAR | P32238 | 7/20 | 0.35 |
| ▸ | CCKBR | P32239 | 7/20 | 0.35 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.35 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12673959 | 0.91 | GLP1R (0.53) | GLP1RGLO1CCKARCCKBRFOLH1 | |
| SCHEMBL12673965 | 0.91 | GLP1R (0.53) | GLP1RGLO1CCKARCCKBRFOLH1 | |
| SCHEMBL12673961 | 0.91 | GLP1R (0.53) | GLP1RGLO1CCKARCCKBRFOLH1 | |
| SCHEMBL19243827 | 0.91 | GLP1R (0.53) | GLP1RGLO1CCKARCCKBRFOLH1 | |
| SCHEMBL28400628 | 0.90 | GLP1R (0.50) | GLP1RGLO1CCKARCCKBRFOLH1 | |
| SCHEMBL28400630 | 0.90 | GLP1R (0.50) | GLP1RGLO1CCKARCCKBRFOLH1 | |
| SCHEMBL20567468 | 0.90 | GLP1R (0.50) | GLP1RGLO1CCKARCCKBRFOLH1 | |
| SCHEMBL20567466 | 0.90 | GLP1R (0.50) | GLP1RGLO1CCKARCCKBRFOLH1 | |
| SCHEMBL415708 | 0.89 | GLP1R (0.34) | GLP1R | |
| SCHEMBL13025471 | 0.89 | GLP1R (0.53) | GLP1RGLO1CCKARCCKBRNOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10253079-B2 | Functionalized Exendin-4 derivatives | SANOFI (FR) | 2019-04-09 | — | — | US | claimed |
| EP-3400957-A1 | FUNCTIONALIZED EXENDIN-4 DERIVATIVES | Sanofi (FR) | 2018-11-14 | — | — | EP | claimed |
| EP-2934567-B9 | EXENDIN-4 DERIVATIVES AS DUAL GLP1/GIP- OR TRIGONAL GLP1/GIP/GLUCAGON AGONISTS | SANOFI SA (FR) | 2018-08-22 | — | — | EP | claimed |
| EP-2934567-B1 | EXENDIN-4 DERIVATIVES AS DUAL GLP1/GIP- OR TRIGONAL GLP1/GIP/GLUCAGON AGONISTS | SANOFI SA (FR) | 2018-05-09 | — | — | EP | claimed |
| EP-2934568-B1 | DUAL GLP1/GIP OR TRIGONAL GLP1/GIP/GLUCAGON AGONISTS | SANOFI SA (FR) | 2017-10-18 | — | — | EP | claimed |
| US-9745360-B2 | Dual GLP1/GIP or trigonal GLP1/GIP/glucagon agonists | SANOFI (FR) | 2017-08-29 | — | — | US | claimed |
| EP-2906595-B1 | EXENDIN-4 DERIVATIVES AS DUAL GLP1/GLUCAGON AGONISTS | SANOFI SA (FR) | 2017-08-16 | — | — | EP | claimed |
| US-20170216406-A1 | FUNCTIONALIZED EXENDIN-4 DERIVATIVES | SANOFI (FR) | 2017-08-03 | — | — | US | claimed |
| EP-2934566-B1 | EXENDIN-4 DERIVATIVES AS DUAL GLP1/GIP OR TRIGONAL GLP1/GIP/GLUCAGON AGONISTS | SANOFI SA (FR) | 2017-06-21 | — | — | EP | claimed |
| US-9670261-B2 | Functionalized exendin-4 derivatives | SANOFI (FR) | 2017-06-06 | — | — | US | claimed |
| US-9181305-B2 | Exendin-4 peptide analogues | SANOFI (FR) | 2015-11-10 | — | — | US | claimed |
| US-20140221281-A1 | DUAL GLP1/GIP OR TRIGONAL GLP1/GIP/GLUCAGON AGONISTS | SANOFI (FR) | 2014-08-07 | — | — | US | claimed |
| US-20140213513-A1 | Exendin-4 Derivatives as dual GLP1/GIP or trigonal GLP1/GIP/Glucagon Agonists | SANOFI (FR) | 2014-07-31 | — | — | US | claimed |
| US-20140206608-A1 | Exendin-4 Derivatives | SANOFI (FR) | 2014-07-24 | — | — | US | claimed |
| US-20140206609-A1 | Functionalized Exendin-4 Derivatives | SANOFI (FR) | 2014-07-24 | — | — | US | claimed |
| WO-2024003313-A1 | NEW PEPTIDES AS SELECTIVE IL-23 RECEPTOR ANTAGONISTS | SANOFI (FR) | 2024-01-04 | — | — | WO | disclosed |
| US-10758592-B2 | Exendin-4 derivatives as dual GLP1/glucagon agonists | SANOFI (FR) | 2020-09-01 | — | — | US | disclosed |
| WO-2014096145-A1 | EXENDIN-4 DERIVATIVES AS DUAL GLP1/GIP OR TRIGONAL GLP1/GIP/GLUCAGON AGONISTS | SANOFI (FR) | 2014-06-26 | — | — | WO | disclosed |
| WO-2014096150-A1 | DUAL GLP1/GIP OR TRIGONAL GLP1/GIP/GLUCAGON AGONISTS | SANOFI (FR) | 2014-06-26 | — | — | WO | disclosed |
| WO-2014056872-A1 | EXENDIN-4 DERIVATIVES AS DUAL GLP1/GLUCAGON AGONISTS | SANOFI (FR) | 2014-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140206608-A1 | Exendin-4 Derivatives | GLP1R, MC4R, NPY4R | GLP1R 1/4885GLO1 3072/4885CCKAR 50/4885 |
| US-20170216406-A1 | FUNCTIONALIZED EXENDIN-4 DERIVATIVES | GLP1R, NPY4R, MC4R | GLP1R 1/4885GLO1 2518/4885CCKAR 39/4885 |
| US-10758592-B2 | Exendin-4 derivatives as dual GLP1/glucagon agonists | GLP1R, GIPR, MC4R | GLP1R 1/4885GLO1 2175/4885CCKAR 35/4885 |
| US-20140206609-A1 | Functionalized Exendin-4 Derivatives | GLP1R, NPY4R, MC4R | GLP1R 1/4885GLO1 2518/4885CCKAR 39/4885 |
| US-20140213513-A1 | Exendin-4 Derivatives as dual GLP1/GIP or trigonal GLP1/GIP/Glucagon Agonists | GLP1R, GIPR, GCGR | GLP1R 1/4885GLO1 1464/4885CCKAR 43/4885 |
| US-10253079-B2 | Functionalized Exendin-4 derivatives | GLP1R, NPY4R, MC4R | GLP1R 1/4885GLO1 2518/4885CCKAR 39/4885 |
| US-20140221281-A1 | DUAL GLP1/GIP OR TRIGONAL GLP1/GIP/GLUCAGON AGONISTS | GLP1R, GIPR, GCGR | GLP1R 1/4885GLO1 1447/4885CCKAR 61/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.